Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2016

Open Access 01-12-2016 | Research article

Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor

Authors: Sarah Daakour, Leon Juvenal Hajingabo, Despoina Kerselidou, Aurelie Devresse, Richard Kettmann, Nicolas Simonis, Franck Dequiedt, Jean-Claude Twizere

Published in: BMC Cancer | Issue 1/2016

Login to get access

Abstract

Background

Perturbed genotypes in cancer can now be identified by whole genome sequencing of large number of diverse tumor samples, and observed gene mutations can be used for prognosis and classification of cancer subtypes. Although mutations in a few causative genes are directly linked to key signaling pathways perturbation, a global understanding of how known cancer genes drive oncogenesis in human is difficult to assess.

Methods

We collected available information about mutated genes in Acute Lymphoblastic Leukemia (ALL). Validated human protein interactions (PPI) were collected from IntAct, HPRD and BioGRID interactomics databases, or obtained using yeast two-hybrid screening assay.

Results

We have mapped interconnections between 116 cancer census gene products associated with ALL. Combining protein-protein interactions data and cancer-specific gene mutations information, we observed that 63 ALL-gene products are interconnected and identified 37 human proteins interacting with at least 2 ALL-gene products. We highlighted exclusive and coexistence genetic alterations in key signaling pathways including the PI3K/AKT and the NOTCH pathways. We then used different cell lines and reporter assay systems to validate the involvement of EXT1 in the Notch pathway.

Conclusion

We propose that novel ALL-gene candidates can be identified based on their functional association with well-known cancer genes. We identified EXT1, a gene not previously linked to ALL via mutations, as a common interactor of NOTCH1 and FBXW7 regulating the NOTCH pathway in an FBXW7-dependend manner.
Appendix
Available only for authorised users
Literature
1.
Forbes SA et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43:D805–11.CrossRefPubMed
2.
3.
Hindorff LA et al. Potential etiologic and functional implications of genome-wide association loci for human diseases and traits. Proc Natl Acad Sci. 2009;106:9362–7.CrossRefPubMedPubMedCentral
4.
March HN et al. Insertional mutagenesis identifies multiple networks of cooperating genes driving intestinal tumorigenesis. Nat Genet. 2011;43:1202–9.CrossRefPubMedPubMedCentral
5.
Starr TK et al. A Transposon-Based Genetic Screen in Mice Identifies Genes Altered in Colorectal Cancer. Science (New York, NY). 2009;323:1747–50.CrossRefPubMedCentral
6.
Takeda H et al. Transposon mutagenesis identifies genes and evolutionary forces driving gastrointestinal tract tumor progression. Nat Genet. 2015;47:142–50.CrossRefPubMed
7.
8.
9.
10.
11.
Parsons DW et al. The genetic landscape of the childhood cancer medulloblastoma. Science (New York, NY). 2011;331:435–9.CrossRef
12.
Tomasetti C, Marchionni L, Nowak MA, Parmigiani G, Vogelstein B. Only three driver gene mutations are required for the development of lung and colorectal cancers. Proc Natl Acad Sci. 2015;112:118–23.CrossRefPubMed
13.
Shtivelman E, Lifshitz B, Gale RP, Canaani E. Fused transcript of abl and bcr genes in chronic myelogenous leukaemia. Nature. 1985;315(6020):550–4.CrossRefPubMed
14.
15.
16.
Torrano V, Procter J, Cardus P, Greaves M, Ford AM. ETV6-RUNX1 promotes survival of early B lineage progenitor cells via a dysregulated erythropoietin receptor. Blood. 2011;118:4910–8.CrossRefPubMed
17.
Zhou M-h et al. Detection of ETV6 gene rearrangements in adult acute lymphoblastic leukemia. Ann Hematol. 2012;91:1235–43.CrossRefPubMed
18.
Tijchon E, Havinga J, Van Leeuwen FN, Scheijen B. B-lineage transcription factors and cooperating gene lesions required for leukemia development. Leukemia. 2013;27:541–52.CrossRefPubMed
19.
20.
Hajingabo LJ et al. Predicting interactome network perturbations in human cancer: application to gene fusions in acute lymphoblastic leukemia. Mol Biol Cell. 2014;25:3973–85.CrossRefPubMedPubMedCentral
21.
Jeong H, Mason SP, Barabasi AL, Oltvai ZN. Lethality and centrality in protein networks. Nature. 2001;411:41–2.CrossRefPubMed
22.
23.
Kerrien S et al. IntAct-open source resource for molecular interaction data. Nucleic Acids Res. 2007;35:D561–5.CrossRefPubMed
24.
Mishra GR et al. Human protein reference database-2006 update. Nucleic Acids Res. 2006;34:D411–4.CrossRefPubMed
25.
Breitkreutz B-J et al. The BioGRID Interaction Database: 2008 update. Nucleic Acids Res. 2008;36:D637–40.CrossRefPubMed
26.
Cline MS et al. Integration of biological networks and gene expression data using Cytoscape. Nat Protocols. 2007;2:2366–82.CrossRefPubMed
27.
Rual J-F et al. Towards a proteome-scale map of the human protein-protein interaction network. Nature. 2005;437:1173–8.CrossRefPubMed
28.
29.
Aerts S et al. Gene prioritization through genomic data fusion. Nat Biotech. 2006;24:537–44.CrossRef
30.
31.
Weng AP et al. Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia. Science. 2004;306:269–71.CrossRefPubMed
32.
33.
Kabir N, Rönnstrand L, Kazi J. FLT3 mutations in patients with childhood acute lymphoblastic leukemia (ALL). Med Oncol. 2013;30:1–3.
34.
Serinsöz E et al. Aberrant expression of β-catenin discriminates acute myeloid leukaemia from acute lymphoblastic leukaemia. Br J Haematol. 2004;126:313–9.CrossRefPubMed
35.
36.
37.
Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005;5:172–83.CrossRefPubMed
38.
Secker-Walker LM et al. Variable Philadelphia breakpoints and potential lineage restriction of bcr rearrangement in acute lymphoblastic leukemia. Blood. 1988;72:784–91.PubMed
39.
de Oliveira GAP, Rangel LP, Costa DC, Silva JL. Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Frontiers in Oncology. 2015;5:97.CrossRefPubMedPubMedCentral
40.
41.
Simmons AD et al. A Direct Interaction Between EXT Proteins and Glycosyltransferases is Defective in Hereditary Multiple Exostoses. Hum Mol Genet. 1999;8:2155–64.CrossRefPubMed
42.
43.
Zhang F et al. Exome Sequencing and Functional Analysis Identifies a Novel Mutation in EXT1 Gene That Causes Multiple Osteochondromas. PLoS One. 2013;8:e72316.CrossRefPubMedPubMedCentral
44.
Crusio KM, King B, Reavie LB, Aifantis I. The ubiquitous nature of cancer: the role of the SCF (Fbw7) complex in development and transformation. Oncogene. 2010;29:4865–73.CrossRefPubMedPubMedCentral
45.
Metadata
Title
Systematic interactome mapping of acute lymphoblastic leukemia cancer gene products reveals EXT-1 tumor suppressor as a Notch1 and FBWX7 common interactor
Authors
Sarah Daakour
Leon Juvenal Hajingabo
Despoina Kerselidou
Aurelie Devresse
Richard Kettmann
Nicolas Simonis
Franck Dequiedt
Jean-Claude Twizere
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2016
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-016-2374-2

Other articles of this Issue 1/2016

BMC Cancer 1/2016 Go to the issue

Research article

Treatment of a chemoresistant neuroblastoma cell line with the antimalarial ozonide OZ513

Research article

Tumor slice culture system to assess drug response of primary breast cancer

Research article

Novel germline mutations and unclassified variants of BRCA1 and BRCA2 genes in Chinese women with familial breast/ovarian cancer

Research article

Expression of AE1/p16 promoted degradation of AE2 in gastric cancer cells

Research article

Socio-economic deprivation: a significant determinant affecting stage of oral cancer diagnosis and survival

Case report

A case report of a patient with metastatic ocular melanoma who experienced a response to treatment with the BRAF inhibitor vemurafenib
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits